Bivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK Stock

China Bivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK Stock, Find details about China Bivalirudin, 128270-60-0 from Bivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK Stock

Model NO.
128270-60-0
CAS
128270-60-0
Appearance
White Freeze-Dried Powder
Storage
Room Temperature Away From Light
Shelf Life
24month
Deliver Time
7-10 Days
Trademark
Biocar
Transport Package
10vials/Kit
Specification
1gram 10gram 1kg
Origin
Guangzhou China
HS Code
2935900090
Model NO.
128270-60-0
CAS
128270-60-0
Appearance
White Freeze-Dried Powder
Storage
Room Temperature Away From Light
Shelf Life
24month
Deliver Time
7-10 Days
Trademark
Biocar
Transport Package
10vials/Kit
Specification
1gram 10gram 1kg
Origin
Guangzhou China
HS Code
2935900090
Bivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK Stock
Bivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK Stock
Detailed Product Information
 
Product Name : Bivalirudin
Trade Name:DPHE-PRO-ARG-PRO-GLY-GLY-GLY-GLY-ASN-GLY-ASP-PHE-GLU-GLU-LLE-PRO-GLU-GLU-TYR-LEU
CAS No.:128270-60-0
Molecular Formula: C98H138N24O33
Molecular Weight:2180.29g/mol
Purity : 98% HPLC
Appearance:  Lyophilized Powder
Typical use:Anticoagulants
Shelf Life :2 years

Payment Terms:T/T, Western Union, Money Gram
Storage:Refrigeration keep dry and away from light.
Bivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK Stock
Description:

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).

Bivalirudin is a kind of synthetic novel anticoagulants(DTI). It is the direct, specific and reversible inhibitor of thrombin.  Its anticoagulant ingredient is a kind of 20 peptides derived from hirudin. Bivalirudin can specifically bind with catalytic site and the anion binding site of whether thrombin that is in the blood circulation or thrombus-bound thrombin, thus directly inhibiting thrombin activity. And its role is characterized by short, reversible. Early clinical studies show that the anticoagulation treatment of bivalirudin is good. And the incidence of bleeding events is low. So its use is safer than traditional heparin therapy. It is mainly used for the prevention of angioplasty interventional treatment of ischemic complications of unstable angina pectoris before and after. 
 
Bivalirudin has a inhibitory effect on soluble and thrombus-bound thrombin in vitro. That effect cannot be affected by products that are released by platelet, and it can extend plasma activated partial thromboplastin time, thrombin time and prothrombin time of normal human with a dose-dependent manner. It is suitable for percutaneous coronary intervention (PCI) unstable angina.
Clinically experiments prove that bivalirudin is more effective than the current mainstream unfractionated heparin/low molecular weight heparin and platelet glycoprotein receptor antagonist in applications around PCI.

Application:
1. It can significantly reduce the incidence of bleeding in elective PCI patients. The total clinical outcome risk fell 14%.
2. It does not cause antibody-mediated thrombocytopenia.
3. Reversibly bind with thrombin. Short half-life. Hard to develop ischemic and hemorrhagic complications. 
4. It is not mainly excreted through the kidneys and can be safely used in patients with renal impairment
 
COA
 
ItemStandardTest Results
IdentificationA.H-NMR:Comply with the structureComplies
 B.LC-MS:Comply with the structureComplies
 C.The IR spectrum of sample should be identical with that of reference standard;Complies
 D.HPLC-ESI-MS
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Complies
Crystallinitymeets the requirements.Complies
Loss on drying≤2.0%0.19%
Heavy metals≤10 ppm<10ppm
Water≤1.0%0.1%
Sulphated ash≤0.5%, determined on 1.0 g.0.009%
Related substancesUnspecified impurities: for each impurity<0.10%
 Total Impurity0.18%
Purity≥99.0%99.7%
Assay99.0%~101.0% (anhydrous substance).99.8%
Microbiological Analysis  
Total plate count≤1000cfu/gComplies
Yeast and Moulds≤100cfu/gComplies
E. Coli.AbsentNegative
SalmonellaAbsentNegative
S.aureusAbsentNegative
StoragePreserve in well-closed, light-resistant and airtight containers.Complies
 
 
 
Bivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK StockBivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK StockBivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK StockBivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK StockBivalirudin Trifluoroacetate CAS 128270-60-0 High Quality Pharmaceutical Peptide UK Stock